Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma
Bone Marrow Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
GD2 synthase mRNA is a sensitive response marker of neuroblastoma in the bone marrow. It is particularly useful for minimal residual disease evaluation and may potentially be useful as an early predictor of resistance to antibody plus GM-CSF immunotherapy.